To date, the most prominent success in NK cell adoptive transfer has been with IL-15-enhanced CAR-NK products against CD19-expressing lymphomas, while progress in other hematologic malignancies and solid tumor targets remain in earlier investigational stages [6,181,185]. This evidence concerns the gene IL15 and hematologic disorder.